Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Kirkland, Washington Clinical Trials

A listing of Kirkland, Washington clinical trials actively recruiting patient volunteers.

RESULTS

Found (14) clinical trials

To Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine

Safety and tolerability of treatment with atogepant for the prevention of episodic migraine over the course of one year

Phase

4.24 miles

Learn More »

Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells

This NANT trial will determine the maximum tolerated dose (MTD) of autologous expanded natural killer (NK) cells when combined with standard dosing of ch14.18 and will assess the feasibility of adding lenalidomide at the recommended Phase II dose of the expanded NK cells with ch14.18, for treatment of children with ...

Phase

4.57 miles

Learn More »

A Study to Investigate the Efficacy Safety and Tolerability of JNJ-42165279 in Adolescent and Adult Participants With Autism Spectrum Disorder

The purpose of this study is to evaluate the efficacy of JNJ-42165279 compared with placebo in the improvement of symptoms of Autism Spectrum Disorder (ASD) during 12 weeks of treatment using the Autism Behavior Inventory (ABI).

Phase

4.57 miles

Learn More »

Study of Tozuleristide and the Canvas Imaging System in Pediatric Subjects With CNS Tumors Undergoing Surgery

Subjects who provide voluntary written informed consent, or have it provided by their legally acceptable representative, will be screened for eligibility. Subjects meeting all of the inclusion and none of the exclusion criteria will be eligible to participate. Surgical excision will occur at least 1 hour and no more than ...

Phase

4.57 miles

Learn More »

Induced Gingivitis & Intra-oral Imaging

The study will include the following phases - 1) Hygiene phase of 2 weeks; 2) Gingivitis induction phase with stent lasting up to 2 weeks; and 3) Resolution phase of 2 weeks. The intervention will consist of cessation of oral hygiene versus an active control of oral hygiene with a ...

Phase N/A

4.81 miles

Learn More »

A Phase 1 Study to Evaluate SNDX- 6352 in Subjects With Active cGVHD

This is dose escalation study in patients with active chronic graft versus host disease who have received at least 2 lines of prior therapy including ibrutinib.

Phase

7.23 miles

Learn More »

A Pilot Study of Oraxol in Subjects With Cutaneous Angiosarcoma

Oraxol will be administered once daily for 3 consecutive days every week during the Treatment Period from Weeks 1 through 25. Subjects who do not have documented disease progression by the end of the Treatment Period will be eligible to receive therapy in the Treatment Extension Period; Oraxol may be ...

Phase

7.23 miles

Learn More »

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

This is a phase III study evaluating the efficacy, safety, and tolerability of olaparib versus placebo when given in addition to abiraterone to genetically unselected patients with metastatic castration-resistant prostate cancer (mCRPC) who have not received prior chemotherapy or new hormonal agents (NHAs) for metastatic castration-resistant prostate cancer (mCRPC) (first-line ...

Phase

7.23 miles

Learn More »

The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.  

Phase

7.3 miles

Learn More »

A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recently Diagnosed Type 1 Diabetes Mellitus (T1D)

This Phase 1b/2a, multi-center study will be conducted in participants with clinical recent-onset Type 1 Diabetes Mellitus (T1D). The primary objective of this study is to assess the safety and tolerability of different doses of AG019 alone as well as AG019 in association with teplizumab. The secondary objectives of this ...

Phase

7.35 miles

Learn More »